Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Cinisello Balsamo – page 104

2 955 clinical trials in Cinisello Balsamo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Cinisello Balsamo at a glance
2 955
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 955 trials in Cinisello Balsamo

Open in trial search

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Phase II Study of Cemiplimab to Spare Surgery in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fondazione GONO Plus

Pancreatic carcinoma

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Cemiplimab, Platinum and Gemcitabine in Treatment‑Naïve Patients with Advanced Squamous Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cemiplimab
  • Sponsor:G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Taletrectinib
  • Sponsor:Nuvation Bio Inc.

Thyroid cancer+1

Not yet recruiting

Study of levothyroxine sodium plus liothyronine sodium vs levothyroxine sodium to control TSH in advanced thyroid cancer patients on tyrosine kinase inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Levothyroxine Sodium
  • Sponsor:Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.

Effect of serenoa repens on chronic prostate inflammation in men with benign prostatic hyperplasia: a phase III randomized study

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Serenoa repens
  • Sponsor:Azienda Ospedaliero Universitaria Careggi

Long‑Term Monitoring of Malignancy Risk in Early‑Onset Metachromatic Leukodystrophy Patients Treated with atidarsagene autotemcel

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Muscular dystrophy

Not yet recruiting

Long-Term Safety and Efficacy of Oral Ribitol in Participants with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ribitol
  • Sponsor:ML Bio Solutions Inc.

Hepatocellular carcinoma

Not yet recruiting

Phase 2 Study of Durvalumab + Tremelimumab with Lenvatinib vs Durvalumab + Tremelimumab Alone in Patients with Unresectable Hepatocellular Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Cinisello Balsamo

What the registry says about research in the country

01 Mental Health Research

Innovative research focusing on Major Depressive Disorder with concurrent insomnia symptoms, evaluating new combination therapies alongside existing antidepressant treatments. Studies examine the effectiveness of adjunctive medications in improving depressive symptoms and sleep patterns.

  • Depression with Insomnia
  • Antidepressant Augmentation
  • Long-term Treatment Efficacy

Research aims to enhance treatment outcomes for patients who haven't responded adequately to conventional therapies.

02 Cardiovascular Studies

Advanced clinical research examining atherosclerotic cardiovascular disease prevention and treatment. Studies include innovative approaches to blood clot prevention in patients with irregular heartbeat who have undergone stent procedures.

  • Primary ASCVD Prevention
  • Anticoagulation Therapy
  • Post-PCI Treatment

Investigations focus on reducing major adverse cardiac events and improving patient outcomes.

03 Metabolic Disorders

Comprehensive studies targeting severe hypertriglyceridemia and related metabolic conditions. Multiple trials are evaluating new therapeutic approaches for managing elevated triglyceride levels and associated cardiovascular risks.

  • Triglyceride Management
  • Metabolic Disease Treatment
  • Cardiovascular Risk Reduction

Research focuses on developing effective treatments for patients with severe lipid disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.